Prescription Patterns and Factors Related to the Number of Medications in Chronic Obstructive Pulmonary Disease in Non-elderly Adults.
- Author:
Chae won MOON
1
;
Hyun O RA
;
Sandy Jeong RHIE
Author Information
1. Department of Pharmacy, Seoul St. Mary's Hospital, Seoul 06591, Republic of Korea.
- Publication Type:Original Article
- Keywords:
Chronic obstructive pulmonary disease;
non-elderly adults
- MeSH:
Adult*;
Animals;
Cats;
Diagnosis;
Humans;
Lung;
Medical Records;
Prescriptions*;
Pulmonary Disease, Chronic Obstructive*;
Retrospective Studies;
Spirometry
- From:Korean Journal of Clinical Pharmacy
2016;26(4):298-305
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: This study is to investigate the prescription patterns and factors related to the number of medications treating chronic obstructive pulmonary disease (COPD) in patients under 65 years old according to GOLD guidelines. METHODS: We retrospectively analyzed the medical records of patients aged 40-64 years with a diagnosis of COPD from January to March 2016. Patients were classified by combined assessment of COPD (grades A, B, C, D) using spirometry, exacerbation history, mMRC, and/or CAT results. We analyzed prescribed medications, treatment options and factors related to the numbers of COPD medications. RESULTS: The total number of prescriptions were 251. About 35.5% of patients were classified as GOLD A, 34.2% as GOLD B, 17.1% as GOLD C and 13.2% as GOLD D. Inhaled bronchodilator was prescribed for 86.9% of patients and the most frequent COPD medication was long-acting muscarinic antagonist (LAMA) followed by inhaled corticosteroids/long acting beta agonist (ICS/LABA). The majority of low risk patients (GOLD A/B) were prescribed a monotherapy with LAMA or LABA. For high risk patients (GOLD C/D), combination treatment with ICS+LAMA+LABA was mostly prescribed. The 21.2% of patients in GOLD D received systemic corticosteroid. The average number of medications per prescription was 3.7, and this number increased with increasing COPD grade, COPD duration and lung function reduction (FEV₁, FEV₁/FVC). CONCLUSION: Generally high adherence to GOLD guideline recommendations was reported. Given the progressive nature of the disease, results suggest that closer attention to respiratory symptoms for early detection, diagnosis, and appropriate treatment of COPD is warranted.
